Utomilumab - CISMeF

Preferred Label : Utomilumab;

NCIt definition : A human, agonistic immunoglobulin (Ig) G2 monoclonal antibody (mAb) targeting 4-1BB (CD137, TNFRSF9), with potential immunostimulating activity. Upon administration, utomilumab binds to and activates 4-1BB expressed on various immune cells, such as CD8-positive and CD4-positive T cells and natural killer (NK) cells. This enhances 4-1BB-mediated signaling, induces cytokine production and promotes anti-tumor immune responses. 4-1BB, a member of the tumor necrosis factor (TNF)/nerve growth factor (NGF) family of receptors, plays an important role in the regulation of immune responses.;

UNII : 6YY8O697VF;

CAS number : 1417318-27-4;

Molecule name : PF 5082566; PF-05082566; PF-2566; PF 05082566;

Details

Origin ID

C116619;

UMLS CUI

C4331488;

Automatic exact mappings (from CISMeF team)
- utomilumab [MeSH concept]
Currated CISMeF NLP mapping
- utomilumab [MeSH Supplementary Concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- utomilumab [MeSH Supplementary Concept]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_target
- Tumor Necrosis Factor Receptor Superfamily Member 9 [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients